<DOC>
	<DOCNO>NCT00911326</DOCNO>
	<brief_summary>The purpose study determine false negative rate ( FNR ) associate Lymphoseek-identified sentinel lymph node ( SLNs ) relative pathological status non-sentinel lymph node elective neck dissection ( END ) head &amp; neck squamous cell carcinoma ( HNSCC ) . NEO3-06 ( study ) Phase 3 clinical trial design supplement NEO3-05 , complete Phase 3 clinical trial conduct patient breast cancer melanoma . NEO3-05 design establish Lymphoseek effective radio-diagnostic agent use intraoperative localization lymph tissue ( node ) lymphatic pathway drain primary site tumor .</brief_summary>
	<brief_title>Evaluation Sentinel Lymph Nodes Head Neck Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Dextrans</mesh_term>
	<mesh_term>Technetium Tc 99m Pentetate</mesh_term>
	<criteria>Subjects meet follow inclusion criterion end screen phase consider admission study : 1 . The patient provide write informed consent Health Insurance Portability Accountability Act ( HIPAA ) authorization participate study . 2 . The patient diagnosis primary squamous cell carcinoma head neck either cutaneous intraoral anatomically locate : mucosal lip , buccal mucosa , low alveolar ridge , upper alveolar ridge , retromolar gingiva ( retromolar trigone ) , floor mouth , hard palette oral ( mobile ) tongue , stage T1T4a , N0 , M0 . 3 . Clinical nodal staging ( N0 ) confirm negative result contrast CT scan gadoliniumenhanced MRI lateral central neck ultrasound . PET scan use evaluation . 4 . Imaging regional nodal basin perform within 30 day plan lymphadenectomy . 5 . The patient candidate surgical intervention , intraoperative lymphatic mapping END include surgical plan . 6 . Patients prior malignancy allow provided patient meet follow criterion : Underwent potentially curative therapy prior malignancy deem low risk recurrence ; AND No malignancy past 5 year ( except effectively treat basal cell squamous cell skin cancer , carcinoma situ cervix effectively treat surgery alone , lobular carcinoma situ ipsilateral contralateral breast treat surgery alone , carcinoma mouth situ minimally invasive ) evidence recurrence . 7 . The patient least 18 year age time consent . 8 . The patient Eastern Cooperative Oncology Group ( ECOG ) status Grade 0 2 . 9 . If patient female , patient confirm negative pregnancy test within 72 hour prior administration Lymphoseek , OR documentation surgical sterilization , OR document evidence postmenopausal status least 1 year . Patients meet follow exclusion criterion end screen phase enrol study : 1 . The patient diagnosis squamous cell carcinoma head neck follow anatomical area : nonmobile base tongue , oral pharynx , nasal pharynx , hypopharynx larynx . 2 . The patient pregnant lactating . 3 . The patient clinical radiological evidence metastatic cancer regional lymph node . 4 . Patients history neck dissection , gross injury neck would preclude reasonable surgical dissection study , radiotherapy neck . 5 . Patients nuclear image study conduct within 15 day consent . 6 . The patient actively receive systemic cytotoxic chemotherapy . 7 . Patient currently participate another investigational drug study participate within 30 day prior consent . 8 . Patient immunosuppressive antimonocyte immunomodulatory therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>HNSCC</keyword>
</DOC>